Oncology

Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast cancer patients after neoadjuvant therapy. This research supports ctDNA for post-neoadjuvant risk st

Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting

Amy A. Kirkwood MSc

BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cance

Mary Eapen Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008 IN THIS EDITION: Greater Role for Umbilical Cord Blood

Francesco Zaja The exciting recent ASH conference reflected the vibrant mood of an America boldly tackling economic and political turmoil with post-presidential-election optimism. Peter Goodwin and Ge

Robert Pirker Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price, Christie Hospital, Manchester Gianni Bonadonna, I

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some

Charles Hsu CHARLES HSU, Johns Hopkins University, Baltimore Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Stephen Jones STEPHEN JONES, US Oncology Research, Houston Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival adva

Markus Heiss REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 MARKUS HEISS, Klinikum Cologne, Merheim For patients with malignant ascites as a

Volker Diehl George Canellos Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy REFERENCE: Abstract 8015, ASCO Annual Meeting Chicago June 1-5, 2007 VOLKER DI

Aimery de Gramont Robert Mayer MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer REFERENCE: 4007, ASCO Annual Meeting Chicago Ju

Josep Llovet Robert Mayer Sorafenib The ‘New Standard’ for Advanced Liver Cancer REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007 JOSEP LLOVET, IDIBAPS H

Bernard Escudier Dean Bajorin Bevacizumab in Advanced Kidney Cancer: Another Treatment Gives Benefit in First Line REFERENCE: ABSTRACT 3, ASCO Annual Meeting Chicago June 1-5, 2007 BERNARD ESCUDIER, G

Ben Slotman Roy Herbst Prophylactic Cranial Irradiation: Fewer Brain Metastases, Longer Survival for Patients with Small Cell Lung Cancer REFERENCE: ABSTRACT 4, ASCO Annual Meeting Chicago June 1-5, 2

Alberto Sobrero Cetuximab With Irinotecan: Phase III Study Shows Benefit in Patients with Oxaliplatin-Refractory Colorectal Cancer REFERENCE: ABSTRACT LB-2; AACR 2007, Los Angeles, Plenary Session ALB

PETER HARPER, Guy’s Hospital, London REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville Bisphosphonates may be more suited

George Canellos Robert Motzer Hormone Replacement Therapy: Better Survival With Colorectal Cancer REFERENCE: J Clin Oncol 24:5680-5686 GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston Using postm

DAVID JABLONS, University of California, San Francisco REFERENCE: Keynote Lecture, Perspectives in Lung Cancer Conference, 2-3 March 2007, Seville, Spain Cell signalling using the Wnt pathway may hold

Lorie Hughes Rachel Ellsworth Rowan Chlebowski Victor Vogel Local Excision Alone for Selected Patients with Ductal Carcinoma In Situ? REFERENCE: Abstract: 29 LORIE HUGHES, The Hope Center, Cartersvill